Laurus Labs gets USFDA nod for Metformin Hydrochloride Tablets USP

The product and API will be commercialized from company’s unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh, the company said in the filing.

Aug 30, 2018 06:08 IST India Infoline News Service

Laurus Labs
Laurus Labs has received an approval from United States Food and Drug Administration (USFDA) for Metformin Hydrochloride Tablets USP 500mg, 850mg and 1000mg which are used for treatment of diabetes.

The product and API will be commercialized from company’s unit 2 located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh, the company said in the filing.

Metformin Hydrochloride Tablets USP 500mg, 850mg, and 1000mg are therapeutically equivalent to Glucophage Tablets 500mg, 850mg, and 1000 mg of Bristol-Myers Squibb Company, the company added.

Laurus Labs Ltd is currently trading at Rs442.50 up by Rs3.8 or 0.87% from its previous closing of Rs438.70 on the BSE.
The scrip opened at Rs455.10 and has touched a high and low of Rs464.35 and Rs442.10 respectively. 

Related Story